Bionano Genomics, Inc.(BNGO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,805 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
BNGO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Bionano Genomics, Inc. (BNGO), a Technology sector company. 13F Pro's AI-powered ranking engine scores BNGO at 10.6/100 on a 32-signal composite quality model, placing it at rank #2,805 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (5.7) and revenue scale (6.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Bionano Genomics, Inc. reports quarterly revenue of $6.7M, net income of $-8.3M, free cash flow of $-5.7M. Top institutional holders of BNGO by reported 13-F value include GEODE CAPITAL MANAGEMENT,, CARRET ASSET MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BNGO trades on the Nasdaq exchange and files with the SEC under CIK 1411690. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BNGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bionano Genomics, Inc. directly from SEC EDGAR. Bionano Genomics, Inc.'s 13F Pro composite quality score has ranged between 9 and 28 since 2022, currently 10.6 — a declining long-term trajectory across 24 quarterly and live scoring snapshots.
Revenue
Q1 2026
$6.7M
Net Income
Q1 2026
$-8.3M
Free Cash Flow
Q1 2026
$-5.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-14.8% YoYNet Income
+51.8% YoYOperating Income
+51.7% YoYEPS (Diluted)
+78.4% YoYTotal Assets
-64.2% YoYTotal Debt
Op. Cash Flow
+44.9% YoY| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $30.8M -14.8% | $36.1M +29.9% | $27.8M +54.6% | $18.0M +111.5% | $8.5M -16.1% | $10.1M |
| Net Income | $-112.0M +51.8% | $-232.5M -75.3% | $-132.6M -83.1% | $-72.4M -76.2% | $-41.1M -37.9% | $-29.8M |
| Operating Income | $-104.0M +51.7% | $-215.2M -63.4% | $-131.7M -70.8% | $-77.1M -100.0% | $-38.6M -49.0% | $-25.9M |
| EPS (Diluted) | $-88.13 +78.4% | $-408.60 -8821.4% | $-4.58 -1661.5% | $-0.26 | — | — |
| Total Assets | $76.7M -64.2% | $214.4M -30.3% | $307.5M -18.5% | $377.1M +523.8% | $60.5M +100.1% | $30.2M |
| Total Debt | — | — | — | $0.00 -100.0% | $16.3M -59.4% | $40.2M |
| Operating Cash Flow | $-68.9M +44.9% | $-125.2M -0.3% | $-124.8M -73.5% | $-71.9M -87.7% | $-38.3M -29.7% | $-29.5M |
Get alerted when BNGO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Bionano Genomics, Inc. including:
Top Institutional Holders of BNGO
GEODE CAPITAL MANAGEMENT, LLC
$196.0K167,533 shCARRET ASSET MANAGEMENT, LLC
$81.9K70,000 shVANGUARD CAPITAL MANAGEMENT LLC
$79.7K68,109 shVANGUARD FIDUCIARY TRUST CO
$60.3K51,578 shRENAISSANCE TECHNOLOGIES LLC
$57.0K48,700 shPRUDENTIAL FINANCIAL INC
$32.8K28,000 shNORTHERN TRUST CORP
$24.0K20,519 shTWO SIGMA SECURITIES, LLC
$21.1K18,056 shEngineers Gate Manager LP
$13.9K11,853 shBlackRock, Inc.
$11.6K9,937 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $196.0K | 167,533 |
| CARRET ASSET MANAGEMENT, LLC | $81.9K | 70,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $79.7K | 68,109 |
| VANGUARD FIDUCIARY TRUST CO | $60.3K | 51,578 |
| RENAISSANCE TECHNOLOGIES LLC | $57.0K | 48,700 |
| PRUDENTIAL FINANCIAL INC | $32.8K | 28,000 |
| NORTHERN TRUST CORP | $24.0K | 20,519 |
| TWO SIGMA SECURITIES, LLC | $21.1K | 18,056 |
| Engineers Gate Manager LP | $13.9K | 11,853 |
| BlackRock, Inc. | $11.6K | 9,937 |
More Technology Companies
View all Technology →Put BNGO on your watchlist
Track score changes the day Bionano Genomics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BNGO a good stock to buy?
13F Pro's AI-powered analysis of Bionano Genomics, Inc. (BNGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BNGO are available on the BNGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own BNGO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BNGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Bionano Genomics, Inc.'s investment landscape.